[{"symbol": "KYMR", "price": 69.54, "beta": 2.217, "volAvg": 946304, "mktCap": 5490113460, "lastDiv": 0, "range": "19.445-103", "changes": -1.58, "companyName": "Kymera Therapeutics, Inc.", "currency": "USD", "cik": "0001815442", "isin": "US5015751044", "cusip": "501575104", "exchange": "NASDAQ Global Market", "exchangeShortName": "NASDAQ", "industry": "Biotechnology", "website": "https://www.kymeratx.com", "description": "Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.", "ceo": "Nello Mainolfi", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "208", "phone": "857 285 5300", "address": "200 Arsenal Yards Boulevard", "city": "Watertown", "state": "MA", "zip": "02472", "dcfDiff": 78.56097, "dcf": -9.020966524930133, "image": "https://images.financialmodelingprep.com/symbol/KYMR.png", "ipoDate": "2020-08-21", "defaultImage": false, "isEtf": false, "isActivelyTrading": true, "isAdr": false, "isFund": false}]